Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 9/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.36 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.34 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.34 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.34 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.33 |
| ▸ | AURKA | O14965 | 1/20 | 0.32 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16675969 | 0.83 | TRPA1 (0.37) | GRM4TRPA1KCNQ3KCNQ2KCNQ1 | |
| SCHEMBL16675911 | 0.78 | NPC1 (0.39) | CYP2D6NTRK1AURKACYP1A2 | |
| SCHEMBL18556887 | 0.77 | CYP2D6 (0.48) | CYP2D6AURKARPS6KB1 | |
| SCHEMBL16675939 | 0.72 | CDK2 (0.39) | GRM4CYP2D6MAPK1AURKARPS6KB1 | |
| SCHEMBL16667689 | 0.71 | CLK2 (0.52) | CYP2D6NTRK1AURKARPS6KB1CYP1A2 | |
| SCHEMBL16667690 | 0.71 | CLK2 (0.52) | CYP2D6NTRK1AURKARPS6KB1CYP1A2 | |
| SCHEMBL18159978 | 0.69 | CYP2D6 (0.39) | GRM4KCNQ3KCNQ2KCNQ1CYP2D6 | |
| SCHEMBL16675917 | 0.68 | NPY5R (0.43) | CYP2D6NTRK1AURKACYP1A2GSK3B | |
| SCHEMBL16682180 | 0.67 | CYP2D6 (0.51) | CYP2D6CYP1A2 | |
| SCHEMBL16797227 | 0.66 | CYP2D6 (0.42) | GRM4TRPA1KCNQ3KCNQ2KCNQ1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9580391-B2 | Saturated acyl guanidine for inhibition of F1F0-ATPase | LYCERA CORPORATION (US) | 2017-02-28 | — | — | US | disclosed |
| US-9580391-B2 | Saturated acyl guanidine for inhibition of F1F0-ATPase | LYCERA CORPORATION (US) | 2017-02-28 | — | — | US | disclosed |
| US-20150119439-A1 | SATURATED ACYL GUANIDINE FOR INHIBITION OF F1F0-ATPASE | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2015-04-30 | — | — | US | disclosed |
| US-20150119439-A1 | SATURATED ACYL GUANIDINE FOR INHIBITION OF F1F0-ATPASE | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2015-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150119439-A1 | SATURATED ACYL GUANIDINE FOR INHIBITION OF F1F0-ATPASE | ATP5F1A, ATP5F1D, ATP5F1C | GRM4 1007/4885TRPA1 4248/4885KCNQ3 2418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.